Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Community study demonstrates Keppra’s use in various pain types

21.03.2003


New data shows that the antiepileptic drug Keppra (levetiracetam), when used alone and in combination with other treatments, provided relief to more than 90 percent of patients with a range of pain syndromes, from migraine headaches to neck and back pain. The study of 400 patients, conducted by the Statesville Pain Associates of Statesville, N.C., was presented today at the American Pain Society’s 22nd Annual Scientific Meeting.



"To date, studies of Keppra to treat pain have been conducted in small patient populations only. Our study of hundreds of patients showed that Keppra was well tolerated and has the potential to be an effective pain treatment alone or in combination with gabapentin, the current ’gold standard’ for the treatment of neuropathic pain," said Douglas Pritchard, M.D., pain specialist and lead investigator of the study. "As pain specialists, we’re always searching for more treatment options. It’s been encouraging to see this response to treatment in such a wide variety of pain states."

Each year chronic pain affects 70 million Americans, or approximately one in every four people, and contributes to 40 million doctor visits. The burden of pain also results in 515 million lost workdays, and accounts for $100 billion in medical expenses each year.1


Investigators determined that 372 of 400 patients involved in the study responded to Keppra, currently approved by the U.S. Food and Drug Administration for the adjunctive treatment of partial onset seizures in adults. Keppra was given as a stand-alone treatment or in combination with gabapentin, another antiepileptic drug (AED) used to treat pain, to 400 patients experiencing migraine headaches, neck, back, nerve, diabetic and complex regional pain syndromes.

This retrospective analysis was of 400 patients given Keppra over a six-month period as a stand-alone drug (n=30%) and in combination with gabapentin (n=70%). Five percent of the patients in this study were treated for migraine headaches and the others were treated for various types of pain including, neck pain (20%), back pain (40%), nerve pain (15%), diabetic pain (15%) and complex regional pain syndromes (5%). Keppra was titrated to dosages between 1,000 and 2,000 mg/day, throughout the duration of treatment (one to six months).

Participants also evaluated their own pain using the visual analog scale (VAS), in which pain is evaluated on a scale of 0-10, with 10 signifying the highest degree of pain. Before starting treatment with Keppra, patients rated their pain between 7 and 10, but within five to 10 days, their self-evaluated VAS scores fell to 5 and 6. The patients’ pain relief was also evaluated by a patient global assessment of pain indicating good pain relief as well as improved function and quality of life.

The most common side effects associated with the use of Keppra in this analysis were drowsiness and nausea.


About Statesville Pain Associates
The pain management team at Statesville Pain Associates strives to minimize patients’ pain, restore their ability to function and ultimately enable them to enjoy a better quality of life. Headed by Dr. Douglas Pritchard and Dr. Bobby Kearney, Statesville Pain Associates treats over 800 patients a month using a multidimensional and a multidisciplinary approach.

Jessica Balaban | EurekAlert!
Further information:
http://www.ncps-cpr.com

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

Im Focus: Quantum-physical Model System

Computer-assisted methods aid Heidelberg physicists in reproducing experiment with ultracold atoms

Two researchers at Heidelberg University have developed a model system that enables a better understanding of the processes in a quantum-physical experiment...

Im Focus: Glacier bacteria’s contribution to carbon cycling

Glaciers might seem rather inhospitable environments. However, they are home to a diverse and vibrant microbial community. It’s becoming increasingly clear that they play a bigger role in the carbon cycle than previously thought.

A new study, now published in the journal Nature Geoscience, shows how microbial communities in melting glaciers contribute to the Earth’s carbon cycle, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

New quantum liquid crystals may play role in future of computers

21.04.2017 | Physics and Astronomy

A promising target for kidney fibrosis

21.04.2017 | Health and Medicine

Light rays from a supernova bent by the curvature of space-time around a galaxy

21.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>